ID   LB831-BLC
AC   CVCL_1370
SY   LB831BLC; LB831
DR   CLO; CLO_0037159
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   cancercelllines; CVCL_1370
DR   Cell_Model_Passport; SIDM00181
DR   ChEMBL-Cells; CHEMBL3308853
DR   ChEMBL-Targets; CHEMBL2366222
DR   Cosmic; 753584
DR   Cosmic-CLP; 753584
DR   DepMap; ACH-002266
DR   EGA; EGAS00001000978
DR   GDSC; 753584
DR   GEO; GSM1670039
DR   IARC_TP53; 21467
DR   LINCS_LDP; LCL-1707
DR   PharmacoDB; LB831BLC_826_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1370
DR   TOKU-E; 3997
DR   Wikidata; Q54902093
RX   PubMed=9637538;
RX   PubMed=11051255;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=29732388;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium.
CC   Population: Caucasian.
CC   HLA typing: A*03,24:03; B*44:03,49:01; C*04:01,07 (PubMed=9637538).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Tyr (c.722C>A); ClinVar=VCV000376663; Zygosity=Homozygous (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0.49%; East Asian, North=0%; East Asian, South=0.01%; South Asian=2.75%; European, North=63.52%; European, South=33.23% (PubMed=30894373).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 12
ST   D5S818: 12,13
ST   D7S820: 10,12
ST   TH01: 8,9
ST   TPOX: 8,10
ST   vWA: 16,17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_E913 ! LB831-EBV
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 34
//
RX   PubMed=9637538; DOI=10.4049/jimmunol.160.12.6188;
RA   Gueguen M., Patard J.-J., Gaugler B., Brasseur F., Renauld J.-C.,
RA   Van Cangh P.J., Boon T., van den Eynde B.J.;
RT   "An antigen recognized by autologous CTLs on a human bladder
RT   carcinoma.";
RL   J. Immunol. 160:6188-6194(1998).
//
RX   PubMed=11051255;
RA   Gala J.-L., Loric S., Guiot Y., Denmeade S.R., Gady A., Brasseur F.,
RA   Heusterspreute M., Eschwege P., De Nayer P., Van Cangh P.J., Tombal B.;
RT   "Expression of prostate-specific membrane antigen in transitional cell
RT   carcinoma of the bladder: prognostic value?";
RL   Clin. Cancer Res. 6:4049-4054(2000).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//